Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

Physics researchers at the UFS receive awards from the NSTF
2009-05-28

 
 Dr Martin Ntwaeaborwa and Prof. Hendrik Swart from the Department of Physics at the University of the Free State.
Yesterday evening two researchers from the Department of Physics at the University of the Free State (UFS) received prestigious awards from the National Science and Technology Forum (NSTF) during its eleventh gala-award ceremony. The event was held at the Emperors Palace in Johannesburg.

Prof. Hendrik Swart, Head of the Department of Physics, was the recipient of the award for research capacity development over the last five to ten years. He received the award for his significant contribution towards the development of students in niche areas of nanophysics. The award, sponsored by Eskom, includes a prize of R100 000 which will be used for research purposes.

Prof. Swart is actively involved in the research of phosphor material, concentrating on the effectiveness of nanophosphor.

Dr Martin Ntwaeaborwa, senior lecturer in the Department of Physics was the recipient of the T.W. Kambule National Research Foundation (NRF) award in Category J as distinguished young black male researcher over the last two to five years. He received the award for his contribution to the understanding and harnessing of light emitting nanomaterials for application in light emitting devices. The awarded includes R100 000 prize money towards Dr Ntwaeaborwa’s research.

Dr Ntwaeaborwa is an expert in luminescent nanomaterials.

A first-year student of Dr Ntwaeaborwa, Thabo Ngobeni also received a Technology and Human Resources for Industry Programme (THRIP) bursary at the gala event.

The NSTF awards give recognition to the outstanding contributions of individuals and groups to science, engineering and technology. This includes all practicing scientists, engineers and technologists across the system of innovation, including, for example, teachers and students in mathematics, science and technology. The NSTF represents government, science councils, professional bodies, higher education, business and civil society.

Altogether 13 individuals and corporate organisations or institutions were presented with the NSTF Awards trophy by the Minister of Science and Technology, Ms Naledi Pandor.

Media Release
Issued by: Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt.stg@ufs.ac.za  
27 May 2009

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept